Migraine during breastfeeding
Not recommended
Migraine in nursing mothers with menstrually-related pattern (short prophylaxis 5-6 days per cycle). Dose 2.5 mg 1-2 times daily. For routine acute attacks, not first-line due to long T½.
Triptan, selective 5HT1B/1D receptor agonist
ATC code: N02CC07 (Frovatriptan)
Brand names
Frova
Activates 5HT1B/1D receptors on dural vessels and the trigeminal system. The ~26-hour half-life – the longest among triptans – makes it convenient for short-course prophylaxis of menstrual migraine. CYP1A2 metabolism.
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
Migraine in nursing mothers with menstrually-related pattern (short prophylaxis 5-6 days per cycle). Dose 2.5 mg 1-2 times daily. For routine acute attacks, not first-line due to long T½.
1 pair found. Sorted from critical to minor.
Mechanism
Frovatriptan is a serotonin agonist, CYP1A2 substrate. With phenelzine – fatal serotonin syndrome.
Symptoms
Agitation, tachycardia, hyperthermia, myoclonus, hyperreflexia within hours.
Management
Combination contraindicated. 14 days after MAOI withdrawal before starting triptan.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Direct links to regulator labels. Open in a new tab.
AEMPS Category C. The long half-life (~26 hours, the longest among triptans) means prolonged fetal exposure after each dose. Post-marketing registries do not show clear teratogenicity, but exposure samples are small. SEN positions paracetamol as first-line for acute migraine in pregnancy; sumatriptan is the best-studied triptan. Frovatriptan is reserved for severe menstrual migraine when safer options have failed.
Compatible with caution. Hale L3. T½ 26 h – longest among triptans, risk of milk accumulation. Used for menstrually-related migraine, not daily. In nursing mothers, prefer sumatriptan or eletriptan.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Frovatriptan is evaluated for the following indications with varying evidence strength: Migraine during breastfeeding (evidence tier C). See the full indication matrix with dosing and citations above on this page.
Common side effects of Frovatriptan (≥ 1 in 100): Dizziness, Somnolence, Hot flushes, Paraesthesia, Chest or throat tightness (non-ischaemic), Nausea. See the Safety section for uncommon and serious reactions.
FDA category C. AEMPS Category C. The long half-life (~26 hours, the longest among triptans) means prolonged fetal exposure after each dose. Post-marketing registries do not show clear teratogenicity, but exposure samples are small. SEN positions paracetamol as first-line for acute migraine in pregnancy; sumatriptan is the best-studied triptan. Frovatriptan is reserved for severe menstrual migraine when safer options have failed.
Compatible with caution. Hale L3. T½ 26 h – longest among triptans, risk of milk accumulation. Used for menstrually-related migraine, not daily. In nursing mothers, prefer sumatriptan or eletriptan.
Frovatriptan is contraindicated in: Hypersensitivity to triptans or sulfonamides; Ischaemic heart disease, prior myocardial infarction, Prinzmetal angina; Uncontrolled hypertension; Cerebrovascular disease and prior transient ischaemic attack; Peripheral arterial disease. Full list in the Safety section.